All In Biotech

Drug Trial Radar · NCT01307098

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

An Open-Label Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SBC-102 in Adult Participants With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency

Last checked: Nov 20, 2026Latest source record: Dec 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

9

Actual

Start

Apr 25, 2011

Primary completion

Jan 6, 2012

Study completion Jan 6, 2012

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was the first clinical study of SBC-102 (sebelipase alfa) for the treatment of Lysosomal Acid Lipase (LAL) Deficiency. It was an open-label dose escalation study in adult participants with liver dysfunction due to LAL Deficiency and was designed to examine 3 doses of sebelipase alfa. The targeted number for this study was 9 evaluable participants.

Conditions

  • Cholesterol Ester Storage Disease(CESD)
  • Lysosomal Acid Lipase Deficiency
  • LAL-Deficiency

Interventions

  • Sebelipase alfa 0.35 mg/kgDrug

    Sebelipase alfa is a recombinant human lysosomal acid lipase.

  • Sebelipase alfa 1 mg/kgDrug

    Sebelipase alfa is a recombinant human lysosomal acid lipase.

  • Sebelipase alfa 3 mg/kgDrug

    Sebelipase alfa is a recombinant human lysosomal acid lipase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number Of Participants Reporting TEAEs And Infusion-Related Reactions (IRRs)Time frame: Screening up to Day 52

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Stanford, California

  • Site not named

    New York, New York

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Prague, Czechia

  • Site not named

    Paris, France

  • Site not named

    Cambridge, United Kingdom

  • Site not named

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.